Samsung Bioepis to Present Post-hoc Analysis of Phase 3
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May ...
Source: globenewswire.com
Soliris Product News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Soliris Product. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Soliris Product Today - Breaking & Trending Today
Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI
EPYSQLI, a biosimilar referencing Soliris1 (eculizumab), is Samsung Bioepis' first biosimilar in hematology to be recommended for marketing authorization by the European Medicines Agency INCHEON, Korea
Source: finanznachrichten.de
Investegate |Samsung Bioepis Announcements | Samsung Bioepis: Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI™
Investegate announcements from Samsung Bioepis, Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI™
Source: investegate.co.uk
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
Phase 3 study demonstrated clinical equivalence in efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SB12 compared to reference eculizumab in paroxysmal nocturnal hemoglobinuria
Source: finanznachrichten.de
Investegate |Samsung Bioepis Announcements | Samsung Bioepis: Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
Investegate announcements from Samsung Bioepis, Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022
Source: investegate.co.uk